SLC5A2 and hydrops fetalis: As mentioned above, it should be noted that in the case of RDN evidently proving its benefit in HF patients in future randomized studies, the intervention will be accompanied by long-term medical treatment with the current pillars of pharmacotherapy for HF, which include already known neuromodulatory agents (beta-blockers), as well as the more recently established SGLT2 inhibitors, which show significant clinical benefit in both HFrEF and HFpEF, mostly due to their pleiotropic effects in cardiovascular homeostasis.